$0.45
-0.03 (-5.34%)
Open$0.46
Previous Close$0.48
Day High$0.49
Day Low$0.43
52W High$988.50
52W Low—
Volume—
Avg Volume182.1K
Market Cap9.09M
P/E Ratio—
EPS$-72.45
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,385.6% upside
Current
$0.45
$0.45
Target
$11.19
$11.19
$8.32
$11.19 avg
$14.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.88M | 4.46M | 5.44M |
| Net Income | -169,945 | -168,167 | -171,039 |
| Profit Margin | -3.5% | -3.8% | -3.2% |
| EBITDA | -214,177 | -200,655 | -244,682 |
| Free Cash Flow | -155,731 | -123,018 | -136,236 |
| Rev Growth | -8.5% | +21.3% | +21.2% |
| Debt/Equity | 0.77 | 0.64 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |